Aus study flags mortality risk with colchicine for cardiac patients
The randomised trial examining clinical utility of colchicine in acute coronary syndrome failed to find a benefit in reduced CV events
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
Professor Jamie Layland.
An Australian trial of colchicine added to standard medical therapy failed to significantly affect CV outcomes in patients with acute coronary syndromes (ACS), researchers say.
And the study, across 17 hospitals, found a higher rate of
